New hope for infertility? drug trial aims to boost birth rates in common uterine condition
NCT ID NCT07162961
Summary
This study is testing whether adding the drug nintedanib to standard hormone therapy can help women with adenomyosis have a successful pregnancy. It will involve 328 women with infertility and adenomyosis who have frozen embryos ready for transfer. Participants will take either the standard therapy alone or the standard therapy plus nintedanib for three months before their embryo transfer procedure to see which group has more live births.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOMYOSIS OF UTERUS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.